Previous close | 32.28 |
Open | 32.28 |
Bid | 22.00 |
Ask | 32.00 |
Strike | 850.00 |
Expiry date | 2026-01-16 |
Day's range | 32.28 - 32.28 |
Contract range | N/A |
Volume | |
Open interest | 167 |
Regeneron (REGN) and Lexicon (LXRX) are in the spotlight following drug approval and regulatory update, respectively.
REGN's oncology portfolio gets a boost with the approval of odronextamab for treating follicular lymphoma and diffuse large B-cell lymphoma (DLBCL).
HRMY vs. REGN: Which Stock Is the Better Value Option?